Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable ...
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Clinical Trials Arena on MSN
GRIN Therapeutics begins phase III trial of radiprodil for NDD
"GRIN Therapeutics begins Phase III trial of radiprodil for NDD" was originally created and published by Clinical Trials ...
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 ...
The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...
Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease ...
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback